



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

# PRODUCT INFORMATION



## C6 NBD Lactosylceramide (d18:1/6:0)

Item No. 22828

CAS Registry No.: 474943-04-9

Formal Name: N-[(1S,2R,3E)-1-[[[4-O-β-D-galactopyranosyl-β-D-glucopyranosyl]oxy]methyl]-2-hydroxy-3-heptadecen-1-yl]-6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-hexanamide

Synonyms: C6 NBD LacCer, C6 NBD Lactosylceramide, NBD LacCer(d18:1/6:0), NBD Lactosylceramide (d18:1/6:0)

MF: C<sub>42</sub>H<sub>69</sub>N<sub>5</sub>O<sub>16</sub>


FW: 900.0

Purity: ≥98%

Supplied as: A solid

Storage: -20°C

Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

C-6 NBD lactosylceramide is supplied as a solid. A stock solution may be made by dissolving the C-6 NBD lactosylceramide in the solvent of choice. C-6 NBD lactosylceramide is soluble in a 2:1 (warm) solution of chloroform:methanol.

### Description

C6 NBD Lactosylceramide (d18:1/6:0) is a biologically active derivative of lactosylceramides (d18:1/acyl mixture) (Item No. 16983) that is tagged with a fluorescent C-6 nitrobenzoxadiazole (C-6 NBD; Item No. 18871) group.<sup>1</sup> C6 NBD Lactosylceramide (d18:1/6:0) has been used to study the effects of P-glycoprotein inhibition in lactosylceramide metabolism-based therapeutics for the treatment of cancer.

### Reference

1. Morad, S.A., Davis, T.S., MacDougall, M.R., *et al.* Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer. *Biochem. Pharmacol.* **130**, 21-33 (2017).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/13/2018

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM